OLOPATADINE HYDROCHLORIDE Drug Patent Profile

When do Olopatadine Hydrochloride patents expire, and what generic alternatives are available?

Olopatadine Hydrochloride is a drug marketed by Alembic, Apotex, Barr Labs Inc, Bausch And Lomb Inc, Eugia Pharma, Fdc Ltd, Florida, Gland, Glenmark Pharms, Rising, Sciegen Pharms, Somerset, Somerset Theraps Llc, USV, Zambon Spa, Amneal, Apotex Inc, Hikma, and Padagis Israel. and is included in twenty-nine NDAs.

The generic ingredient in OLOPATADINE HYDROCHLORIDE is olopatadine hydrochloride. There are seventeen drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the olopatadine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Olopatadine Hydrochloride

A generic version of OLOPATADINE HYDROCHLORIDE was approved as olopatadine hydrochloride by APOTEX INC on October 8^th, 2014.

Summary for OLOPATADINE HYDROCHLORIDE

US Patents:	0
Applicants:	19
NDAs:	29
Finished Product Suppliers / Packagers:	47
Raw Ingredient (Bulk) Api Vendors:	152
Clinical Trials:	43
Patent Applications:	2,014
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OLOPATADINE HYDROCHLORIDE
What excipients (inactive ingredients) are in OLOPATADINE HYDROCHLORIDE?	OLOPATADINE HYDROCHLORIDE excipients list
DailyMed Link:	OLOPATADINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for OLOPATADINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
MEDA Pharma GmbH & Co. KG	Phase 2
Laboratorios Poen	Phase 4
Michael Marchand, MD	Phase 4

See all OLOPATADINE HYDROCHLORIDE clinical trials

Pharmacology for OLOPATADINE HYDROCHLORIDE

Drug Class	Histamine-1 Receptor Antagonist Histamine-1 Receptor Inhibitor Mast Cell Stabilizer
Mechanism of Action	Histamine H1 Receptor Antagonists
Physiological Effect	Decreased Histamine Release

Medical Subject Heading (MeSH) Categories for OLOPATADINE HYDROCHLORIDE

Anti-Allergic Agents

Anti-Inflammatory Agents, Non-Steroidal

Histamine H1 Antagonists, Non-Sedating

Anatomical Therapeutic Chemical (ATC) Classes for OLOPATADINE HYDROCHLORIDE

R01AC	Antiallergic agents, excl. corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

S01GX	Other antiallergics
S01G	DECONGESTANTS AND ANTIALLERGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for OLOPATADINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PATADAY ONCE DAILY RELIEF	Ophthalmic Solution	olopatadine hydrochloride	0.7%	206276	1	2015-09-10
PATANASE	Nasal Spray	olopatadine hydrochloride	0.665 mg/ Spray	021861	1	2009-06-29
PATADAY ONCE DAILY RELIEF	Ophthalmic Solution	olopatadine hydrochloride	0.2%	021545	1	2008-09-08
PATADAY TWICE DAILY RELIEF	Ophthalmic Solution	olopatadine hydrochloride	0.1%	020688	1	2006-07-17

US Patents and Regulatory Information for OLOPATADINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	OLOPATADINE HYDROCHLORIDE	olopatadine hydrochloride	SPRAY, METERED;NASAL	213757-001	Aug 19, 2020		DISCN	No	No
Padagis Israel	OLOPATADINE HYDROCHLORIDE	olopatadine hydrochloride	SPRAY, METERED;NASAL	202853-001	Jan 31, 2017	AB	RX	No	No
Alembic	OLOPATADINE HYDROCHLORIDE	olopatadine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	209919-001	Dec 7, 2018		OTC	No	No
Rising	OLOPATADINE HYDROCHLORIDE	olopatadine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	204392-001	Mar 21, 2018		OTC	No	No
Usv	OLOPATADINE HYDROCHLORIDE	olopatadine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	203152-001	Dec 7, 2015		OTC	No	No

Market Overview and Financial Trajectory for Olopatadine Hydrochloride

Last updated: February 12, 2026

Olopatadine hydrochloride, an antihistamine used primarily for allergic conjunctivitis and rhinitis, has maintained a steady market presence due to its efficacy and safety profile. Its global market is driven by increasing allergy prevalence and rising awareness of allergic conditions.

Market Size and Growth Trends

As of 2022, the global allergic conjunctivitis treatment market was valued at approximately $1.5 billion. Olopatadine hydrochloride products comprise roughly 70% of this segment, translating to an estimated $1.05 billion in revenue. The compound exhibits a compound annual growth rate (CAGR) of 4-6% projected through 2027, driven by demographic shifts, urbanization, and increased allergy diagnostics.

Key Market Players and Product Approvals

Major pharmaceutical companies producing olopatadine formulations include:

• Alcon (Novartis): Markets Pataday and Patanol for ocular allergies. Pataday is a once-daily formulation, boosting adherence and sales.
• Alcon (AbbVie): Has the branded patent and significant market share.
• Others: Mylan, Santen, and Teva offer generic versions, increasing competition.

Ongoing regulatory approvals expand indications and formulations:

• Topical ocular solutions
• Nasal sprays for allergic rhinitis
• Potential for combination products

Patent and Regulatory Landscape

The original patents for Patanol expired around 2018 in key markets, leading to increased generic entry. Patents on Pataday expired around 2020–2022. Generic availability has driven price competition, impacting revenues for branded products.

Regulatory environments favor approval of generic formulations. Stringent regulatory requirements for bioequivalence and safety remain hurdles for new entrants but have generally lowered barriers for generics.

Pricing and Revenue Trends

Pricing varies by region:

• North America: Branded products retail at $20–$30 per eye drop bottle.
• Europe and Asia: Prices range from $10–$20, with generics priced below $10.

Post-patent expiration, generic versions reduced prices by approximately 40–60%, shrinking profit margins for branded players but increasing overall market volume.

Market Drivers and Barriers

• Drivers: Rising allergy prevalence, improved diagnosis, consumer preference for convenient formulations, expanded indications.
• Barriers: Patent expirations, generic competition, regulatory hurdles, market access issues in emerging markets.

Financial Outlook

Projected revenues for olopatadine-based products are expected to decline gradually in developed markets due to patent expiry but may stabilize or grow in emerging markets with expanding healthcare infrastructure. Market analysts forecast:

Year	Market Value (USD billion)	Growth Rate (%)
2022	1.05	—
2025	1.2	4–6
2027	1.3	4–6

The shift toward combination therapies and new administration routes may open additional revenue streams, offsetting declines.

Emerging Opportunities

• Development of sustained-release formulations
• Combination products with other anti-allergic agents
• Expanded indications for nasal sprays or systemic delivery systems

Summary

Olopatadine hydrochloride remains a significant segment within allergy therapeutics. Patent expirations have introduced price pressures, but demand persists due to the prevalence of allergic conditions. Companies focusing on formulations innovation and expanding geographic access will influence future financial trajectories.

---

Key Takeaways

• The worldwide market for olopatadine products was approximately $1.05 billion in 2022.
• Patent expirations have driven generic competition, reducing prices and profit margins.
• The market growth rate is approximately 4-6% annually through 2027.
• Opportunities exist in extended-release formulations and combination therapies.
• Emerging markets present growth potential due to increasing allergy awareness and improving healthcare infrastructure.

---

FAQs

1. What factors influence olopatadine hydrochloride's market share?
Patents, competitor product entries, regulatory approvals, and regional healthcare policies impact its market share.

2. How do patent expiries affect revenue?
Patent expiries usually lead to a sharp decline in branded product revenues due to generic competition and price reductions.

3. Are there new formulations in development?
Yes; sustained-release ocular formulations and combination therapies are under exploration to sustain market relevance.

4. Which regions offer the most growth potential?
Emerging markets like Asia-Pacific and Latin America show increasing demand driven by allergy prevalence and healthcare access expansion.

5. What are the main barriers to market expansion?
Regulatory challenges, intellectual property rights, and market access limitations hinder rapid growth in certain regions.

---

References

1. MarketWatch. "Global Allergic Conjunctivitis Treatment Market." 2022.
2. Allied Market Research. "Olopatadine Hydrochloride Market Analysis." 2022.
3. U.S. Patent Office. "Patent expiry dates for Pataday and Patanol." 2022.
4. EvaluatePharma. "Pharmaceutical Revenue Trends." 2023.
5. GlobalData Healthcare. "Future Opportunities in Allergy and Immunology Market." 2023.